📄 chemistry

Development and Validation of a Sensitive LC-MS/MS Method for Quantifying N-Nitroso-Ketamine in Ketamine Hydrochloride Injections

This study establishes a sensitive and validated LC-MS/MS method for quantifying N-nitroso-ketamine in ketamine hydrochloride injections while classifying the impurity as a low-risk Category 5 NDSRI based on its sterically hindered structure and FDA-aligned toxicological assessment.

Original authors: Ramamohana Reddy Maddike, Suresh Babu Kothamasu

Published 2026-06-24

📖 5 min read🧠 Deep dive

CC BY 4.0

Original authors: Ramamohana Reddy Maddike, Suresh Babu Kothamasu

Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). ✨ This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer

Imagine you have a very important medicine called Ketamine, which doctors use to put patients to sleep or help with severe pain. Like any high-quality product, it needs to be pure. However, sometimes tiny, invisible "gremlins" can sneak into the manufacturing process. In this case, the gremlin is a chemical called N-nitroso-ketamine (NNK).

This paper is like a detective story where scientists built a super-powered microscope to find these gremlins, figured out how dangerous they actually are, and proved that the medicine is safe.

Here is the story broken down into simple parts:

1. The Villain: The "Gremlin" (Nitrosamine)

Nitrosamines are a family of chemicals known to be bad news. Think of them as tiny, invisible saboteurs that can damage the body's instruction manual (DNA) and potentially cause cancer.

How they get there: They can form when the medicine (Ketamine) mixes with tiny amounts of nitrite (a common chemical) in acidic conditions, kind of like how rust forms on metal when it meets water and air.
The specific gremlin: In this study, the scientists were looking for a specific version of this gremlin called N-nitroso-ketamine (NNK), which is made specifically from the Ketamine molecule itself.

2. The Risk Assessment: Is the Gremlin Strong or Weak?

Before building a detector, the scientists asked: "How dangerous is this specific gremlin?"

The Analogy: Imagine a lock (the human body's enzymes) trying to pick a lockpick (the gremlin) to break into a house (DNA).
The Twist: The NNK gremlin is wearing a very bulky, heavy coat (steric hindrance). Because of its bulky shape, the "lock" in our body can't easily grab it to activate it. It's like trying to pick a lock with a giant, clumsy glove on.
The Verdict: Because it's so hard for the body to activate this gremlin, the scientists classified it as a Category 5 threat. This is the lowest level of concern. It means the "safe daily limit" for this specific gremlin is actually quite high (1,500 nanograms per day) compared to other, more dangerous nitrosamines.

3. The Detective Tool: The Super-Microscope (LC-MS/MS)

The scientists needed a way to find this gremlin even if it was hiding in a haystack.

Why old tools failed: They first tried using a standard UV light detector (like a regular flashlight). But the gremlin is so faint and the medicine is so bright that the flashlight couldn't see the tiny shadow of the gremlin. It was like trying to see a firefly in a stadium full of spotlights.
The New Tool: They built a LC-MS/MS system. Think of this as a high-tech metal detector combined with a fingerprint scanner.
- LC (Liquid Chromatography): This is a race track. The medicine and the gremlin run down a track. The track is designed so the gremlin gets stuck in traffic while the medicine zooms past, separating them.
- MS/MS (Mass Spectrometry): Once the gremlin is separated, this machine acts like a sniper. It shoots the molecule, breaks it into pieces, and looks for a very specific "fingerprint" (a specific weight pattern: 267 turning into 207). If it sees that exact pattern, it knows, "That's the gremlin!"
The Result: This new tool is incredibly sensitive. It can find the gremlin at levels as low as 139 parts per billion. To visualize that: if you had a swimming pool full of water, this tool could find a single drop of the gremlin hiding in it.

4. The Investigation: Did the Gremlin Show Up?

The scientists tested real bottles of Ketamine injections to see if the gremlin was actually there.

The Stress Test: They tried to force the gremlin to appear by heating the medicine up and keeping it in acidic conditions (the perfect storm for gremlin creation).
The Outcome: Even under these "worst-case" conditions, the gremlin did not appear. The levels were so low they were below the detection limit of their super-microscope.
Why? It turns out the manufacturing process and the ingredients used were so clean that there wasn't enough "fuel" (nitrite) to create the gremlin in the first place.

5. The Conclusion: A Safe Medicine

The paper concludes with a three-part victory:

Toxicology: We know exactly how dangerous the gremlin is (not very, because it's "clumsy" and hard to activate).
Detection: We built a super-sensitive tool that can find the gremlin if it ever tries to hide.
Safety: We tested the actual medicine, and the gremlin wasn't there.

In short: The scientists proved that while Ketamine could theoretically create this bad chemical, the medicine is made in a way that prevents it. They also built a "super-sniffer" that ensures if it ever does appear, we will catch it immediately. The medicine is safe, and the monitoring system is ready.

Technical Summary: Development and Validation of a Sensitive LC-MS/MS Method for Quantifying N-Nitroso-Ketamine in Ketamine Hydrochloride Injections

Problem Statement
Nitrosamine impurities are a critical quality concern in pharmaceuticals due to their mutagenic and carcinogenic potential. Recent regulatory scrutiny by agencies such as the FDA, EMA, and WHO has necessitated rigorous risk assessment and control strategies for Nitrosamine Drug Substance-Related Impurities (NDSRIs). Ketamine hydrochloride, a widely used dissociative anesthetic, contains a secondary amine functional group susceptible to nitrosation under acidic conditions in the presence of nitrite, potentially forming N-nitroso-ketamine (NNK). While the formation mechanism is understood, there is a lack of extensive research regarding the specific toxicological profile of NNK, its structural constraints regarding carcinogenicity, and the development of sensitive analytical methods to quantify it at trace levels in parenteral formulations. Conventional UV detection methods often lack the sensitivity required to detect N-nitrosamines at the parts-per-billion (ppb) levels mandated by regulatory limits.

Methodology
The study employed an integrated approach combining toxicological risk assessment with the development and validation of an ultra-sensitive analytical method.

Toxicological Assessment (CPCA): The carcinogenic potency of NNK was evaluated using the FDA-aligned Carcinogenic Potency Categorization Approach (CPCA). This assessment considered structural factors including $\alpha$ -hydrogen availability, steric hindrance, and metabolic activation potential. The analysis focused on whether the NNK structure allows for cytochrome P450-mediated $\alpha$ -hydroxylation, a prerequisite for forming DNA-reactive intermediates.
Analytical Method Development: A Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) method was developed.
- Chromatography: Separation was achieved on an Acquity HSS T3 column (2.5 µm, 4.6 × 100 mm) at 40°C using a gradient of 0.1% formic acid in water (Mobile Phase A) and 0.1% formic acid in acetonitrile (Mobile Phase B).
- Detection: Electrospray Ionization (ESI) in positive mode with Multiple Reaction Monitoring (MRM) was utilized. The specific transition monitored was the precursor ion $m/z$ 267.0 $\rightarrow$ product ion $m/z$ 207.0.
- Flow Diversion: A timed flow diversion strategy (0.00–0.5 min and 21.5–22.0 min to waste) was implemented to prevent contamination of the mass spectrometer by the high-concentration ketamine matrix.
- Rationale for MS/MS: Photodiode Array (PDA) detection was evaluated but rejected due to the weak UV absorbance of N-nitrosamines and significant spectral overlap with the API and matrix components.
Method Validation: The method was validated according to international regulatory guidelines for specificity, linearity, accuracy, precision (repeatability and intermediate), sensitivity (LOD/LOQ), robustness, and solution stability.
Formulation Stress Testing: The study included stress testing of the formulation under high temperatures (60°C for 30 days) and evaluation of raw material quality (specifically nitrite levels) to assess the risk of NNK formation.

Key Contributions and Results

Toxicological Classification: The structural analysis revealed that while NNK possesses $\alpha$ -hydrogens, the bulky cyclohexanone scaffold creates significant steric hindrance around the $\alpha$ -carbon. This steric protection limits enzymatic accessibility for $\alpha$ -hydroxylation, thereby reducing the formation of DNA-reactive intermediates. Consequently, NNK was classified as CPCA Category 5, the lowest level of carcinogenic concern, establishing an Acceptable Intake (AI) limit of 1500 ng/day. Based on the maximum daily dose of ketamine (1074 mg), this translates to a specification limit of approximately 1397 ppb (1.4 ng/mg).
Analytical Performance: The developed LC-MS/MS method demonstrated high sensitivity and selectivity:
- Linearity: Excellent linearity was observed from the Limit of Quantification (LOQ) to 200% of the specification limit (139 ppb to 2779 ppb) with a correlation coefficient ( $r$ ) > 0.999.
- Sensitivity: The Limit of Detection (LOD) was determined to be 69.5 ppb (S/N > 3), and the LOQ was 139.0 ppb (S/N > 10).
- Accuracy and Precision: Recovery rates ranged from 95% to 104% across LOQ, 100%, and 200% levels. Precision (RSD) was consistently within 5.0% for system suitability and method precision, and 2.0% for intermediate precision.
- Robustness: The method remained robust against variations in flow rate ( $\pm$ 0.2 mL/min) and MS temperature ( $\pm$ 20°C).
Formulation Risk Mitigation: Stress testing and batch analysis of ketamine hydrochloride injections (pH 3.5–5.5) showed no significant formation of NNK even under accelerated thermal conditions. Three commercial batches tested consistently showed NNK levels below the LOQ (139 ppb), confirming that the current manufacturing process and raw material controls effectively mitigate nitrosamine formation.

Significance
The paper presents a comprehensive framework for the management of NDSRIs in ketamine-based formulations. By combining a structure-guided toxicological assessment with a validated, ultra-sensitive analytical method, the study provides a scientifically supported strategy for regulatory compliance. The research highlights that structural constraints (steric hindrance) can significantly lower the carcinogenic potency of specific NDSRIs, justifying higher acceptable intake limits compared to low-molecular-weight nitrosamines. Furthermore, the successful development of an LC-MS/MS method capable of quantifying NNK at sub-ppb levels addresses a critical gap in the analytical monitoring of parenteral formulations, offering a replicable paradigm for risk assessment and control in other pharmaceutical products containing secondary amines.